Volume 22, Issue 12, Pages (December 2014)

Slides:



Advertisements
Similar presentations
Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs  Maria Luisa Jaén, Laia Vilà, Ivet Elias,
Advertisements

Molecular Therapy - Methods & Clinical Development
Use of a Modified α-N-Acetylgalactosaminidase in the Development of Enzyme Replacement Therapy for Fabry Disease  Youichi Tajima, Ikuo Kawashima, Takahiro.
Volume 17, Issue 8, Pages (August 2009)
Volume 22, Issue 4, Pages (April 2014)
Volume 17, Issue 7, Pages (July 2009)
Volume 16, Issue 12, Pages (December 2008)
Volume 22, Issue 8, Pages (August 2014)
Volume 13, Issue 6, Pages (June 2006)
Volume 14, Issue 1, Pages (July 2006)
Volume 19, Issue 5, Pages (May 2011)
Molecular Therapy - Nucleic Acids
Volume 24, Issue 2, Pages (February 2016)
Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII  Brian A. Karolewski,
Long-Term Rescue of a Lethal Inherited Disease by Adeno-Associated Virus–Mediated Gene Transfer in a Mouse Model of Molybdenum-Cofactor Deficiency  S.
Volume 18, Issue 5, Pages (May 2010)
Molecular Therapy - Methods & Clinical Development
Volume 13, Issue 1, Pages (January 2006)
Volume 19, Issue 2, Pages (February 2011)
Volume 15, Issue 12, Pages (December 2007)
Volume 23, Issue 5, Pages (May 2015)
Molecular Therapy - Methods & Clinical Development
Volume 23, Issue 12, Pages (December 2015)
Volume 18, Issue 6, Pages (June 2010)
Volume 9, Issue 4, Pages (April 2004)
Volume 25, Issue 11, Pages (November 2017)
Volume 15, Issue 2, Pages (February 2007)
Volume 9, Issue 6, Pages (June 2004)
Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques  Juliette Hordeaux, Christian Hinderer,
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 11, Pages (November 2010)
Volume 22, Issue 5, Pages (May 2014)
Volume 19, Issue 10, Pages (October 2011)
Molecular Therapy - Nucleic Acids
Volume 24, Issue 7, Pages (July 2016)
Volume 12, Issue 6, Pages (December 2005)
Volume 18, Issue 1, Pages (January 2010)
Volume 6, Issue 1, Pages (July 2002)
Volume 18, Issue 1, Pages (January 2010)
Volume 23, Issue 4, Pages (April 2015)
Volume 14, Issue 1, Pages 5-13 (July 2006)
Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain  Cassia N. Cearley, John.
Volume 12, Issue 5, Pages (November 2005)
Volume 18, Issue 10, Pages (October 2010)
Computer-assisted Hydrodynamic Gene Delivery
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Volume 23, Issue 4, Pages (April 2015)
Volume 22, Issue 4, Pages (April 2014)
Volume 23, Issue 12, Pages (December 2015)
Volume 19, Issue 6, Pages (June 2011)
Volume 13, Issue 3, Pages (March 2006)
Volume 20, Issue 3, Pages (March 2012)
Volume 3, Issue 3, Pages (March 2001)
Volume 6, Issue 3, Pages (September 2002)
Volume 3, Issue 6, Pages (June 2001)
Volume 18, Issue 12, Pages (December 2010)
Volume 18, Issue 6, Pages (June 2010)
Volume 20, Issue 9, Pages (September 2012)
Targeting Root Cause by Systemic scAAV9-hIDS Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice  Haiyan Fu, Kim Zaraspe, Naoko.
Volume 23, Issue 3, Pages (March 2015)
Vinicia Assunta Polito, Maria Pia Cosma 
Volume 20, Issue 2, Pages (February 2012)
Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma  Chien-Kuo.
Volume 18, Issue 7, Pages (July 2010)
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Volume 16, Issue 4, Pages (April 2008)
Volume 16, Issue 4, Pages (April 2008)
Molecular Therapy - Methods & Clinical Development
Delivery of a Retroviral Vector Expressing Human β-Glucuronidase to the Liver and Spleen Decreases Lysosomal Storage in Mucopolysaccharidosis VII Mice 
Volume 23, Issue 4, Pages (April 2015)
Presentation transcript:

Volume 22, Issue 12, Pages 2018-2027 (December 2014) Intrathecal Gene Therapy Corrects CNS Pathology in a Feline Model of Mucopolysaccharidosis I  Christian Hinderer, Peter Bell, Brittney L Gurda, Qiang Wang, Jean-Pierre Louboutin, Yanqing Zhu, Jessica Bagel, Patricia O'Donnell, Tracey Sikora, Therese Ruane, Ping Wang, Mark E Haskins, James M Wilson  Molecular Therapy  Volume 22, Issue 12, Pages 2018-2027 (December 2014) DOI: 10.1038/mt.2014.135 Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 IDUA expression in CSF and serum following IT AAV9 delivery. Five MPS I cats were treated with an intracisternal injection of an AAV9 vector (1012 GC/kg) expressing feline IDUA from a CB (gray symbols) or CMV (black symbols) promoter. CSF and serum were serially collected from the treated animals as well as three untreated MPS I cats. IDUA activity was measured using the fluorogenic substrate 4MU-iduronide in CSF (a) and serum (b). All values are the mean of duplicate assays. Normal serum and CSF activity (dashed line) are the mean values from two wild-type animals. Molecular Therapy 2014 22, 2018-2027DOI: (10.1038/mt.2014.135) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Normalization of CSF hexosaminidase activity despite a transgene-specific antibody response. CSF samples collected before vector administration and at the end of the study were tested for the presence of antibodies against IDUA by indirect ELISA (a). Titers are based on a standard curve of a serially diluted positive sample, which was arbitrarily assigned a titer of 1:1,000. (b) Total Hex activity was measured in CSF using the fluorogenic substrate MUG. Normal activity (dashed line) is the mean of two heterozygous control samples. The untreated MPS I level (dotted line) is the mean of untreated controls. Molecular Therapy 2014 22, 2018-2027DOI: (10.1038/mt.2014.135) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Global CNS transduction and biochemical correction following IT gene transfer. Vector genomes were quantified in DNA extracted from CNS and peripheral tissues of treated cats by TaqMan PCR (a). Tissue samples from MPS I cats and heterozygous controls were collected from sites throughout the CNS for measurement of IDUA activity (b) and Hex activity (c). Treated animals are stratified into those with normal CSF IDUA activity (8911, 8932, 9058) and those with low CSF activity (8982, 9050). All enzyme activities are normalized to protein concentration. Molecular Therapy 2014 22, 2018-2027DOI: (10.1038/mt.2014.135) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Reversal of brain ganglioside storage. Immunostaining for the ganglioside GM3 was performed on tissue sections from four brain regions in untreated MPS I cats (a–d), treated cats with high CSF IDUA activity (e–h) and low CSF activity (i–l), as well as normal controls (m–p). Scale bar = 500 µm. Molecular Therapy 2014 22, 2018-2027DOI: (10.1038/mt.2014.135) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Correction of neuronal storage lesions. Sections from the cerebral cortex were stained with H&E (a,f,k,p). Arrows indicate the distended neuron cell bodies typical of MPS I. The treated cats were stratified into those with low CSF IDUA activity and those with high activity. Cholesterol accumulation was evaluated in matched brain sections by filipin staining in untreated (b,c), treated (g,h,l,m) and normal control (q,r) cats. Immunostaining for the lysosomal integral membrane protein LIMP2 was performed on corresponding sections from each animal (d,e,i,j,n,o,s,t). Scale bar = 500 µm (4×), 200 µm (10×), or 100 µm (H&E). Molecular Therapy 2014 22, 2018-2027DOI: (10.1038/mt.2014.135) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Reduced GAG storage in the cerebral vasculature and meninges. Cortical brain sections were stained for GAGs using Alcian blue. Low magnification images (a,d,g,j) show the cerebral cortex with the associated meninges. High magnification images show representative cortical blood vessels (b,e,h,k) and segments of meninges (c,f,i,l). Scale bars = 500 µm (left column) and 100 µm (middle and right columns). Molecular Therapy 2014 22, 2018-2027DOI: (10.1038/mt.2014.135) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions

Figure 7 Correction of somatic lesions. Sections from heart, lung, liver, spleen, and kidney were stained with Alcian blue. Animals are stratified according to antibody response and circulating enzyme activity as in Figure 6. Scale bar = 100 µm. Molecular Therapy 2014 22, 2018-2027DOI: (10.1038/mt.2014.135) Copyright © 2014 American Society of Gene & Cell Therapy Terms and Conditions